331 related articles for article (PubMed ID: 19273707)
1. Online quality control, hyperfractionated radiotherapy alone and reduced boost volume for standard risk medulloblastoma: long-term results of MSFOP 98.
Carrie C; Grill J; Figarella-Branger D; Bernier V; Padovani L; Habrand JL; Benhassel M; Mege M; Mahé M; Quetin P; Maire JP; Baron MH; Clavere P; Chapet S; Maingon P; Alapetite C; Claude L; Laprie A; Dussart S
J Clin Oncol; 2009 Apr; 27(11):1879-83. PubMed ID: 19273707
[TBL] [Abstract][Full Text] [Related]
2. Conformal radiotherapy, reduced boost volume, hyperfractionated radiotherapy, and online quality control in standard-risk medulloblastoma without chemotherapy: results of the French M-SFOP 98 protocol.
Carrie C; Muracciole X; Gomez F; Habrand JL; Benhassel M; Mege M; Mahé M; Quetin P; Maire JP; Soum F; Baron MH; Clavere P; Chapet S; Gaci Z; Kolodie H; Maingon P; Vie B; Bernier V; Alapetite C; Hoffstetter S; Grill J; Lafay F;
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):711-6. PubMed ID: 15927408
[TBL] [Abstract][Full Text] [Related]
3. Early clinical outcomes demonstrate preserved cognitive function in children with average-risk medulloblastoma when treated with hyperfractionated radiation therapy.
Gupta T; Jalali R; Goswami S; Nair V; Moiyadi A; Epari S; Sarin R
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1534-40. PubMed ID: 22342098
[TBL] [Abstract][Full Text] [Related]
4. Exclusive Hyperfractionated Radiation Therapy and Reduced Boost Volume for Standard-Risk Medulloblastoma: Pooled Analysis of the 2 French Multicentric Studies MSFOP98 and MSFOP 2007 and Correlation With Molecular Subgroups.
Carrie C; Kieffer V; Figarella-Branger D; Masliah-Planchon J; Bolle S; Bernier V; Laprie A; Supiot S; Leseur J; Habrand JL; Alapetite C; Kerr C; Dufour C; Claude L; Chapet S; Huchet A; Bondiau PY; Escande A; Truc G; Nguyen TD; Pasteuris C; Vigneron C; Muracciole X; Bourdeaut F; Appay R; Dubray B; Colin C; Ferlay C; Dussart S; Chabaud S; Padovani L; ;
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1204-1217. PubMed ID: 32768563
[TBL] [Abstract][Full Text] [Related]
5. Concurrent chemotherapy and reduced-dose cranial spinal irradiation followed by conformal posterior fossa tumor bed boost for average-risk medulloblastoma: efficacy and patterns of failure.
Douglas JG; Barker JL; Ellenbogen RG; Geyer JR
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1161-4. PubMed ID: 15001259
[TBL] [Abstract][Full Text] [Related]
6. Patterns of failure using a conformal radiation therapy tumor bed boost for medulloblastoma.
Wolden SL; Dunkel IJ; Souweidane MM; Happersett L; Khakoo Y; Schupak K; Lyden D; Leibel SA
J Clin Oncol; 2003 Aug; 21(16):3079-83. PubMed ID: 12915597
[TBL] [Abstract][Full Text] [Related]
7. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.
Packer RJ; Gajjar A; Vezina G; Rorke-Adams L; Burger PC; Robertson PL; Bayer L; LaFond D; Donahue BR; Marymont MH; Muraszko K; Langston J; Sposto R
J Clin Oncol; 2006 Sep; 24(25):4202-8. PubMed ID: 16943538
[TBL] [Abstract][Full Text] [Related]
8. Longterm treatment results of childhood medulloblastoma by craniospinal irradiation in supine position.
Slampa P; Pavelka Z; Dusek L; Hynkova L; Sterba J; Ondrova B; Princ D; Novotny T; Kostakova S
Neoplasma; 2007; 54(1):62-7. PubMed ID: 17203894
[TBL] [Abstract][Full Text] [Related]
9. Disease control and ototoxicity using intensity-modulated radiation therapy tumor-bed boost for medulloblastoma.
Polkinghorn WR; Dunkel IJ; Souweidane MM; Khakoo Y; Lyden DC; Gilheeney SW; Becher OJ; Budnick AS; Wolden SL
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e15-20. PubMed ID: 21481547
[TBL] [Abstract][Full Text] [Related]
10. Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma.
Mulhern RK; Palmer SL; Merchant TE; Wallace D; Kocak M; Brouwers P; Krull K; Chintagumpala M; Stargatt R; Ashley DM; Tyc VL; Kun L; Boyett J; Gajjar A
J Clin Oncol; 2005 Aug; 23(24):5511-9. PubMed ID: 16110011
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic schedules influence the pattern of intellectual decline after irradiation of posterior fossa tumors.
Kieffer-Renaux V; Viguier D; Raquin MA; Laurent-Vannier A; Habrand JL; Dellatolas G; Kalifa C; Hartmann O; Grill J
Pediatr Blood Cancer; 2005 Nov; 45(6):814-9. PubMed ID: 15924360
[TBL] [Abstract][Full Text] [Related]
12. Combined treatment modality for intracranial germinomas: results of a multicentre SFOP experience. Société Française d'Oncologie Pédiatrique.
Bouffet E; Baranzelli MC; Patte C; Portas M; Edan C; Chastagner P; Mechinaud-Lacroix F; Kalifa C
Br J Cancer; 1999 Mar; 79(7-8):1199-204. PubMed ID: 10098759
[TBL] [Abstract][Full Text] [Related]
13. Low-dose craniospinal irradiation and ifosfamide, cisplatin and etoposide for non-metastatic embryonal tumors in the central nervous system.
Yasuda K; Taguchi H; Sawamura Y; Ikeda J; Aoyama H; Fujieda K; Ishii N; Kashiwamura M; Iwasaki Y; Shirato H
Jpn J Clin Oncol; 2008 Jul; 38(7):486-92. PubMed ID: 18573848
[TBL] [Abstract][Full Text] [Related]
14. White matter lesions detected by magnetic resonance imaging after radiotherapy and high-dose chemotherapy in children with medulloblastoma or primitive neuroectodermal tumor.
Fouladi M; Chintagumpala M; Laningham FH; Ashley D; Kellie SJ; Langston JW; McCluggage CW; Woo S; Kocak M; Krull K; Kun LE; Mulhern RK; Gajjar A
J Clin Oncol; 2004 Nov; 22(22):4551-60. PubMed ID: 15542806
[TBL] [Abstract][Full Text] [Related]
15. Craniospinal radiotherapy in adult medulloblastoma.
Selek U; Zorlu F; Hurmuz P; Cengiz M; Turker A; Soylemezoglu F; Gurkaynak M
Strahlenther Onkol; 2007 May; 183(5):236-40. PubMed ID: 17497094
[TBL] [Abstract][Full Text] [Related]
16. Neuropsychological Outcome of Children Treated for Standard Risk Medulloblastoma in the PNET4 European Randomized Controlled Trial of Hyperfractionated Versus Standard Radiation Therapy and Maintenance Chemotherapy.
Câmara-Costa H; Resch A; Kieffer V; Lalande C; Poggi G; Kennedy C; Bull K; Calaminus G; Grill J; Doz F; Rutkowski S; Massimino M; Kortmann RD; Lannering B; Dellatolas G; Chevignard M;
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):978-985. PubMed ID: 26194675
[TBL] [Abstract][Full Text] [Related]
17. Outcome for patients with metastatic (M2-3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy.
Taylor RE; Bailey CC; Robinson KJ; Weston CL; Walker DA; Ellison D; Ironside J; Pizer BL; Lashford LS
Eur J Cancer; 2005 Mar; 41(5):727-34. PubMed ID: 15763649
[TBL] [Abstract][Full Text] [Related]
18. Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma.
Merchant TE; Kun LE; Krasin MJ; Wallace D; Chintagumpala MM; Woo SY; Ashley DM; Sexton M; Kellie SJ; Ahern V; Gajjar A
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):782-7. PubMed ID: 17892918
[TBL] [Abstract][Full Text] [Related]
19. Radiation treatment for medulloblastoma: a review of 64 cases at a single institute.
Liu Y; Zhu Y; Gao L; Xu G; Yi J; Liu X; Li Y
Jpn J Clin Oncol; 2005 Mar; 35(3):111-5. PubMed ID: 15741299
[TBL] [Abstract][Full Text] [Related]
20. Hyperfractionated radiotherapy and chemotherapy for childhood ependymoma: final results of the first prospective AIEOP (Associazione Italiana di Ematologia-Oncologia Pediatrica) study.
Massimino M; Gandola L; Giangaspero F; Sandri A; Valagussa P; Perilongo G; Garrè ML; Ricardi U; Forni M; Genitori L; Scarzello G; Spreafico F; Barra S; Mascarin M; Pollo B; Gardiman M; Cama A; Navarria P; Brisigotti M; Collini P; Balter R; Fidani P; Stefanelli M; Burnelli R; Potepan P; Podda M; Sotti G; Madon E;
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1336-45. PubMed ID: 15050308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
